Topoisomerase II inhibitors, such as mitoxantrone, are already affiliated with the development of secondary acute myeloid leukemia and myelosuppression. Sufferers who had an incomplete antileukemic response acquired a second induction program wherein mitoxantrone or daunorubicin was administered for two times and cytarabine for five times utilizing the similar every day https://abigailr888ngx9.wikipublicist.com/user